Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes

BACKGROUND: Protein-based Cas9 in vivo gene editing therapeutics have practical limitations owing to their instability and low efficacy. To overcome these obstacles and improve stability, we designed a nanocarrier primarily consisting of lecithin that can efficiently target liver disease and encapsu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Eun Yi, Ryu, Jee-Yeon, Lee, Han A. Reum, Hong, Shin Hee, Park, Hye Sun, Hong, Kwan Soo, Park, Sang-Gyu, Kim, Hong Pyo, Yoon, Tae-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350399/
https://www.ncbi.nlm.nih.gov/pubmed/30696428
http://dx.doi.org/10.1186/s12951-019-0452-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350399/
https://www.ncbi.nlm.nih.gov/pubmed/30696428
http://dx.doi.org/10.1186/s12951-019-0452-8

Ejemplares similares